These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 26453803)

  • 1. Plasma membrane dynamics and tetrameric organisation of ABCG2 transporters in mammalian cells revealed by single particle imaging techniques.
    Wong K; Briddon SJ; Holliday ND; Kerr ID
    Biochim Biophys Acta; 2016 Jan; 1863(1):19-29. PubMed ID: 26453803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).
    Meyer zu Schwabedissen HE; Kroemer HK
    Handb Exp Pharmacol; 2011; (201):325-71. PubMed ID: 21103975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.
    Henriksen U; Gether U; Litman T
    J Cell Sci; 2005 Apr; 118(Pt 7):1417-26. PubMed ID: 15769853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
    Mizuarai S; Aozasa N; Kotani H
    Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of residues in ABCG2 affecting protein trafficking and drug transport, using co-evolutionary analysis of ABCG sequences.
    Haider AJ; Cox MH; Jones N; Goode AJ; Bridge KS; Wong K; Briggs D; Kerr ID
    Biosci Rep; 2015 Jul; 35(4):. PubMed ID: 26294421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABCG2 is a high-capacity urate transporter and its genetic impairment increases serum uric acid levels in humans.
    Nakayama A; Matsuo H; Takada T; Ichida K; Nakamura T; Ikebuchi Y; Ito K; Hosoya T; Kanai Y; Suzuki H; Shinomiya N
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1091-7. PubMed ID: 22132962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A.
    Ejendal KF; Hrycyna CA
    Mol Pharmacol; 2005 Mar; 67(3):902-11. PubMed ID: 15598974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new strategy of high-speed screening and quantitative structure-activity relationship analysis to evaluate human ATP-binding cassette transporter ABCG2-drug interactions.
    Saito H; Hirano H; Nakagawa H; Fukami T; Oosumi K; Murakami K; Kimura H; Kouchi T; Konomi M; Tao E; Tsujikawa N; Tarui S; Nagakura M; Osumi M; Ishikawa T
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1114-24. PubMed ID: 16489126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
    Galetti M; Petronini PG; Fumarola C; Cretella D; La Monica S; Bonelli M; Cavazzoni A; Saccani F; Caffarra C; Andreoli R; Mutti A; Tiseo M; Ardizzoni A; Alfieri RR
    PLoS One; 2015; 10(11):e0141795. PubMed ID: 26536031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane.
    Diop NK; Hrycyna CA
    Biochemistry; 2005 Apr; 44(14):5420-9. PubMed ID: 15807535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
    Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
    Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2.
    Henriksen U; Fog JU; Litman T; Gether U
    J Biol Chem; 2005 Nov; 280(44):36926-34. PubMed ID: 16107343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The multidrug resistance half-transporter ABCG2 is purified as a tetramer upon selective extraction from membranes.
    Dezi M; Fribourg PF; Di Cicco A; Arnaud O; Marco S; Falson P; Di Pietro A; Lévy D
    Biochim Biophys Acta; 2010 Nov; 1798(11):2094-101. PubMed ID: 20691149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the gout-causing Q141K polymorphism and a CFTR ΔF508 mimicking mutation on the processing and stability of the ABCG2 protein.
    Sarankó H; Tordai H; Telbisz Á; Özvegy-Laczka C; Erdős G; Sarkadi B; Hegedűs T
    Biochem Biophys Res Commun; 2013 Jul; 437(1):140-5. PubMed ID: 23800412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding.
    Ejendal KF; Diop NK; Schweiger LC; Hrycyna CA
    Protein Sci; 2006 Jul; 15(7):1597-607. PubMed ID: 16815914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
    Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
    World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single amino acid (482) variants of the ABCG2 multidrug transporter: major differences in transport capacity and substrate recognition.
    Ozvegy-Laczka C; Köblös G; Sarkadi B; Váradi A
    Biochim Biophys Acta; 2005 Feb; 1668(1):53-63. PubMed ID: 15670731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity.
    Xu J; Peng H; Chen Q; Liu Y; Dong Z; Zhang JT
    Cancer Res; 2007 May; 67(9):4373-81. PubMed ID: 17483351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABCG2 dysfunction increases serum uric acid by decreased intestinal urate excretion.
    Takada T; Ichida K; Matsuo H; Nakayama A; Murakami K; Yamanashi Y; Kasuga H; Shinomiya N; Suzuki H
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):275-81. PubMed ID: 24940679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.